InflaRx stock: buy or sell?
August 19th, 2019
InflaRx N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology in the United States.
Should I buy InflaRx stock?Make a decision about when to buy or sell stocks is one of the hardest parts of being a trader or investor. That's why is so important to define your own trading strategy that matches with your character as inversor. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.
Currently, InflaRx stock doesn't match any of these trading strategies, so our recommendation is not to buy.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is InflaRx stock a buy?
Financial institutions and banks post stock ratings everyday.At Stocks2.com, we gathered 7 ratings published for IFRX stock in the last 30 days.
|Date||Analyst / Broker||Previous rating||Current rating|
|2019-6-5||Raymond James||Outperform||Market Perform|
|2019-6-5||JPMorgan Chase & Co.||Overweight||Underweight|
|2019-6-5||Credit Suisse Group||Outperform||Underperform|
|2019-3-29||Robert W. Baird||Outperform||Outperform|
|2019-2-5||JPMorgan Chase & Co.||Overweight||Top Pick|
InflaRx stock analysis
InflaRx ended today at $2.64 and appreciated a tiny 0.38%.
InflaRx closed today at $2.64 and appreciated a tiny 0.38%. Since last June when IFRX stock price broke down the SMA200d line, it slid $-34.65 per share (-92.92%). IFRX marked a lower low and a lower high in the short term, defining a downward trend. Climbing above $2.79 would break this short term down trend and open possibilities for reversing this situation. On April, IFRX hit a new all time high, pushing higher than on April tops. Check different trading setups that use ATHs as triggers.
After sliding for 4 weeks, this week InflaRx stayed constant a slightly fine 0.38%, closing at $2.64. Early August IFRX plummed a bloodcurdling -5.90% in just one week. After 4 weeks sliding, this week raised a 0.37%.
Since price and 40-weeks moving average lines crossed down early June, IFRX fell $-33.35 per share (-92.66%). Trading stocks that are under the 40-weeks (that is, 200-days) moving average mark is not recommended by many experts, as it indicates that the stock has not enough institutional support. Far behind is the all-time high InflaRx hit late April and since then the price is -95.03% below that top.
InflaRx stock price history
InflaRx IPO was on November 8th, 2017 at $15.19 per share1. Since then, IFRX stock sliced a -82.60%, with a yearly average of -82.60%.
1: Adjusted price after possible price splits or reverse-splits.
InflaRx stock historical price chart
IFRX stock reached all-time highs on April with a price of $53.10.
InflaRx stock price target is $34.30How much a stock will be priced tomorrow or next week is quite unpredictable However, many stock price predictions are published every day by banks, financial institutions and independent analysts. The accuracy of these stock price predictions is not very high, and you should not blindly believe and make decisions only based on what this ratings or price target predictions say. For the last month we found 4 price targets for InflaRx stock:
|Date||Analyst / Broker||Action||Previous target||Current target||Diff|
|2019-6-5||JPMorgan Chase & Co.||Downgrades||$67.00||$9.00||-86.6%|
|2019-3-29||Robert W. Baird||Lowers Target||$62.00||$58.00||-6.5%|
|2019-2-5||JPMorgan Chase & Co.||Reiterates||$42.00||$65.00||54.8%|
Financials and fundamental analysis
Earnings date and Earnings per ShareInflaRx presented slightly fine results for 2018-Q4 on March. InflaRx raised Earnings per Share (EPS) by 4.50%, beating experts consensus of $-0.44. InflaRx posted $-0.46.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsCompared to , last anual revenues report draw of to M dollars. When comparing vs , , profit margin (that is, the net income divided by revenues) a to .
Quarterly financial resultsReported quarter income marked $-10.28 M with a profit margin of . Profit margin stayed steady a 0.00% compared to previous quarter when profit margin was inf%. When comparing turnover to same quarter last year, InflaRx sales marked a neutral movement and stayed constant a nan%. Looking back to recent quarterly results, InflaRx posted 7 positive quarters in a row.
InflaRx ownershipWhen you are planning to invest in shares of a stock, it's worth to have a look its ownership structure.
Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For InflaRx, 38.72% of all outstanding shares are owned by its staff.
In case of InflaRx stock, 60.93% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for IFRX stock account 0.00%, no big difference from last month.
For a better understanding, the next table shows ownership data compared to other related stocks:
|Market cap||$62.9 M||$308.9 M||$246.3 M|
|Total shares||23.8 M||120.7 M||49.3 M|
|Float shares||12.8 M||108.6 M||45.0 M|
|- Institutional holdings (%)||60.9%||95.2%||72.8%|
|- Insider holdings (%)||38.7%||2.5%||0.2%|
|Shares in short selling||0.0%||0.0%||0.0%|
|Monday, August 19th, 2019|
|Day range||$2.60 - $2.68|
|Average true range||$0.14|
|50d mov avg||$3.05|
|100d mov avg||$21.75|
|200d mov avg||$27.86|
InflaRx performanceTo better understand InflaRx performance you must becnhmark its gains with other related stocks in same sector or industry. We chose PDL BioPharma and Pieris Pharmaceuticals as the bechmarking frame for InflaRx stock.